Teva Pharmaceutical Industries (NYSE:TEVA) Updates FY 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 2.350-2.650 for the period, compared to the consensus estimate of 2.540. The company issued revenue guidance of $16.8 billion-$17.4 billion, compared to the consensus revenue estimate of $17.1 billion. Teva Pharmaceutical Industries also updated its Q1 2025 guidance to 0.520-0.520 EPS.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Thursday, March 27th. UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Barclays decreased their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. Finally, Bank of America dropped their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $23.43.

Remove Ads

Teva Pharmaceutical Industries Stock Down 0.1 %

Shares of NYSE TEVA traded down $0.02 during midday trading on Tuesday, reaching $15.36. The company's stock had a trading volume of 2,806,870 shares, compared to its average volume of 9,662,554. The stock has a market capitalization of $17.41 billion, a price-to-earnings ratio of -10.58, a PEG ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries has a fifty-two week low of $12.51 and a fifty-two week high of $22.80. The stock has a 50 day simple moving average of $17.08 and a 200-day simple moving average of $18.11. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities research analysts predict that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.